

Contura sells veterinary rights to Antematter

Contura A/S (“Contura”), a wholly owned subsidiary of Speciality European Pharma Limited (“SEP”) is pleased to announce that on 30 December 2014 it completed the sale of worldwide rights to all veterinary uses of its hydrogel technology to Antematter Ip Limited (“Antematter”), a company incorporated in Ireland.

Contura commenced development work on the use of its hydrogel technology for the treatment of osteoarthritis (lameness) in horses in 2011. In 2013 the results of a clinical study of the product in 40 horses reported that at 1, 3 and 6 months respectively, 55%, 65% and 75% of lame horses treated with a single injection of Arthramid[®] Vet were lame free. The comparable results for the control arm of the study (horses treated with triamcinolone and hyaluronic acid) were 15%, 40% and 35%. In addition to the aforementioned 6 month study, a 24 month follow up study is ongoing and due to report in 2015. With the generation of this data Contura decided to monetise its investment in the veterinary uses of its technology.

Under the terms of the sale, Contura receives an up-front cash payment, a deferred cash payment and has entered into a long term supply agreement for veterinary products derived from its hydrogel technology.

Commenting on the termination, Patrick Banks, Director of Contura, said:

“This sale completes one of the commercial milestones set at the time of Contura’s acquisition by SEP in April 2013. We are excited by the opportunity for our hydrogel technology in the veterinary market, but feel that a specialist veterinary partner will be better placed to complete the development of that opportunity. We have developed interesting early data in horses for our hydrogel technology and we have commenced limited sales of a veterinary product, Arthramid[®] Vet in certain markets. Further clinical data is expected in 2015 and further clinical studies of the product are planned. Under the terms of the sale, Contura’s supply agreement with Antematter will ensure that we continue to benefit from the success of Arthramid[®] Vet in the future. Cash generated from the sale will be used to increase investment in the company’s development programmes in man, including our development of Arthroamid[®], the company’s novel treatment for osteoarthritis of the knee.”

About Arthramid[®] Vet

Arthramid[®] Vet is a homogenous hydrophilic hydrogel used in the treatment of lameness in horses and osteoarthritis in companion animals. Contura believes the product may have utility in other veterinary applications.





CONTURA A/S
Sydmarken 23
2860 Søborg

Tel.: +45 81100900
Fax: +45 81100901
info@contura.com
www.contura.com

VAT Registration No. 27 05 77 16

Arthrosamid[®]

Arthrosamid[®] is a polyacrylamide hydrogel under development as a long-acting intra-articular injection for the treatment of osteoarthritis in humans. Development of Arthrosamid[®] commenced after the generation of impressive early clinical data with Arthramid[®] Vet in horses. Patients benefit from both pain relief and improved mobility after treatment with the product.

About SEP

SEP is the parent company of a European group which specialises in the distribution and sale of healthcare products, both pharmaceuticals and medical devices, focused primarily upon the fields of urology and urogynaecology. Its lead products are:

Bulkamid[®]
Aquamid[®]
Mitem[®]
Regurin[®] XL

SEP was founded in 2006 and built an experienced and accomplished management team. In 2013, SEP acquired Contura A/S, a Danish company based in Copenhagen. Contura A/S had two marketed products at the time of its acquisition by SEP, Bulkamid[®] and Aquamid[®]. It also had a number of development programmes focused upon additional uses of its hydrogel technology. SEP has established a sales and marketing infrastructure in the leading European markets, either through its own sales force or through distribution partners. SEP has offices in the UK, Denmark, Germany, France and Italy.

-ENDS-

For further information please contact:

SEP
Patrick Banks, Chief Executive Officer

Tel: +44 (0)20 7421 7400

